---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-009034"
form_type: "8-K"
ticker: "ALLR"
cik: "0001860657"
company_name: "Allarity Therapeutics, Inc."
filed_at: "2024-02-01T23:59:59+00:00"
generated_at: "2026-06-06T11:34:38.492320+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Allarity: Novartis terminates dovitinib license; director Cullem resigns citing misconduct

## Summary
- Novartis terminated dovitinib license on Jan 26, 2024 citing material breach for lack of payment.
- Director James G. Cullem resigned Jan 27, 2024, alleging acts and omissions by Chairman and Board injurious to company.
- Cullem was terminated as CEO for cause on Dec 8, 2023; he claims termination should be without cause.
- Allarity disagrees with Cullem's claims and takes exception to his characterizations.

## SEC filing metadata
- accession: 0001213900-24-009034
- form_type: 8-K
- ticker: ALLR
- cik: 0001860657
- company_name: Allarity Therapeutics, Inc.
- filed_at: 2024-02-01T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.02, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1860657/000121390024009034/0001213900-24-009034-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1860657/000121390024009034/ea192600-8k_allarity.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-009034
- JSON: https://secwatch.observer/filing/0001213900-24-009034.json
- Plain text: https://secwatch.observer/filing/0001213900-24-009034.txt

## Key facts
- Executive change
  James G. Cullem resigned as Director at Allarity Therapeutics, Inc..
  - Action: resigned
  - Role: Director
  source text: On January 27, 2024, the Chairman of our Board of Directors (the “Board”), received email correspondence from Mr. James G. Cullem tendering his resignation (the “Resignation Email”) as a member of our Board.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1860657/000121390024009034/0001213900-24-009034-index.htm
- Material Agreements
  Allarity Therapeutics, Inc. terminated Agreement with Novartis Pharma AG (effective 2024-01-26).
  - Action: termination
  - Agreement: license
  - Counterparty: Novartis Pharma AG
  - Effective: 2024-01-26
  source text: On January 26, 2024, we received written notice from Novartis indicating their decision to terminate the Agreement based on material breach for lack of financial payment.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1860657/000121390024009034/0001213900-24-009034-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.